Skip to main content
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Rankings
Pricing
Log In
Start Free Trial
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Rankings
Pricing
Log In
Start Free Trial
Jean-Louis Pujol
Sign up to set email alerts
368
Publications
6,324
Citation Statements Received
5,459
Citation Statements Given
How they've been cited
9,823
282
6,002
40
How they cite others
8,322
214
5,234
11
Affiliations
Hôpital Arnaud de Villeneuve
,
Centre Hospitalier Universitaire de Montpellier
Publications
Order By: Most citations
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
Barlési
1
,
Mazières
2
,
Merlio
3
et al.
2016
The Lancet
Abstract
Show
1,042
36
669
7
Get access via publisher
Add to collection
Cite
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
Ponce Aix
1
,
Nadal
2
,
Au
3
et al.
2019
The Lancet Oncology
631
34
588
2
Get access via publisher
Add to collection
Cite
PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
Paz-Ares
1
,
de Marinis
2
,
Dediu
3
et al.
2013
JCO
Abstract
Show
634
18
431
3
Get access via publisher
Add to collection
Cite
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial
Paz-Ares
1
,
de Marinis
2
,
Dediu
3
et al.
2012
The Lancet Oncology
582
22
416
5
Get access via publisher
Add to collection
Cite
Perioperative Nivolumab in Resectable Lung Cancer
Cascone
1
,
Awad
2
,
Spicer
3
et al.
2024
N Engl J Med
554
17
340
0
Get access via publisher
Add to collection
Cite
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial
Vansteenkiste
1
,
Cho
2
,
Vanakesa
3
et al.
2016
The Lancet Oncology
521
4
306
0
Get access via publisher
Add to collection
Cite
Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer
Eckardt
1
,
von Pawel
2
,
Pujol
3
et al.
2007
JCO
Abstract
Show
385
12
252
3
Get access via publisher
Add to collection
Cite
Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors
Roch
1
,
Coffy
2
,
Jean-Baptiste
3
et al.
2020
Lung Cancer
Abstract
Show
131
13
148
4
Get access via publisher
Add to collection
Cite
1
2